95 221

Cited 7 times in

Impact of Grade, Hormone Receptor, and HER-2 Status in Women with Breast Cancer on Response to Specific Chemotherapeutic Agents by in vitro Adenosine Triphosphate-based Chemotherapy Response Assay.

Authors
 Ja Seung Koo  ;  Woohee Jung  ;  Eunah Shin  ;  Hy-de Lee  ;  Joon Jeong  ;  Kun-Hong Kim  ;  Hyeongjae Jeong  ;  Soon Won Hong 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.24(6) : 1150-1157, 2009 
Journal Title
 JOURNAL OF KOREAN MEDICAL SCIENCE 
ISSN
 1011-8934 
Issue Date
2009
MeSH
Adenosine Triphosphate/metabolism* ; Adult ; Aged ; Antineoplastic Agents/therapeutic use* ; Breast Neoplasms*/classification ; Breast Neoplasms*/drug therapy ; Breast Neoplasms*/pathology ; Doxorubicin/therapeutic use ; Drug Screening Assays, Antitumor/methods* ; Epirubicin/therapeutic use ; Female ; Fluorouracil/therapeutic use ; Humans ; Middle Aged ; Paclitaxel/therapeutic use ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism* ; Receptors, Estrogen/genetics ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/genetics ; Receptors, Progesterone/metabolism
Keywords
Breast Neoplasms ; Drug Therapy ; Tumor Markers
Abstract
This study was designed to assess whether histological and biological factors of breast cancer can predict chemoresponse to specific agents. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was employed to retrieve chemoresponse to 5-fluorouracil (5-FU), doxetaxel, doxorubicin, epirubicin, and paclitaxel in 49 patients. Tumors with high histologic and nuclear grade have higher response rate to doxorubicin (P<0.05) and palitaxel (P<0.05). Estrogen receptor (ER)-negative tumors respond well to doxorubicin (P=0.038), and progesterone receptor (PR)-negative tumors to 5-FU (P=0.039), doxetaxel (P=0.038), doxorubicin (P=0.000), epirubicin (P=0.010), and paclitaxel (P=0.003). Among the breast cancer subtypes determined by ER, PR, and HER-2 immunohistochemical stains, the HER-2+/ER- subtype has a higher response rate to doxorubicin (P=0.008). This in vitro result suggests that the combination of histologic and nuclear grade, hormone receptor, and HER-2 status can be a predictive factor of response to specific chemotherapy agents. Further in vivo study should be followed for clinical trials
Files in This Item:
T200904943.pdf Download
DOI
10.3346/jkms.2009.24.6.1150
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Biochemistry and Molecular Biology (생화학-분자생물학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Koo, Ja Seung(구자승) ORCID logo https://orcid.org/0000-0003-4546-4709
Kim, Kun Hong(김건홍) ORCID logo https://orcid.org/0000-0001-5639-6372
Lee, Hy De(이희대)
Jung, Woo Hee(정우희)
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
Hong, Soon Won(홍순원) ORCID logo https://orcid.org/0000-0002-0324-2414
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/105586
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse